Media.Player

Method for treatment of drug-resistant HIV-1

詳細技術說明

None

*Abstract

BackgroundNucleoside and nucleotide analog reverse transcriptase inhibitors (NRTI) are integral components of therapies for HIV-1 infection. The currently approved NRTI have significant limitations, however, that include short- and long-term toxicity, pharmacokinetic interactions with or antiretroviral drugs, and the selection of drug-resistant HIV-1 variants that are cross-resistant with other NRTI. Accordingly, there is a critical need to develop new NRTI that have excellent activity and safety profiles and exhibit little or no cross-resistance with existing drugs. TechnologyUsing data derived from such structure-activity-resistance studies, investigators at Pitt have identified a lead class of compounds that retain potent activity against many drug-resistant variants of HIV-1. These nucleoside analogs could fulfill the expanding need for NRTI that are active against drug-resistant HIV-1.Applications:1) Treatment of HIV-1 infection2) Treatment of drug-resistant HIV-1Advantages:1) Active against several drug resistant strains of HIV-1 which include HIV-1 with the drug-resistance mutations K65R, L74V or M184V 2) Active against all strains of HIV-1 that are resistant to AZTNon Provisional and PCT patent applications filed

*Principal Investigation

Name: John Mellors, Professor

Department: Med-Medicine

Name: Nicolas Sluis-Cremer, Assistant Professor

Department: Med-Medicine

國家/地區

美國